Effect of bone marrow derived mononuclear cells in treatment of pediatric with cardiomyopathy
Phase 1
- Conditions
- Dilated cardiomyopathy.I42.0Dilated cardiomyopathy
- Registration Number
- IRCT20080728001031N27
- Lead Sponsor
- Royan Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
LVEF<45% (echocardiography)
Time of Diagnosis > 3m
Resistance to Standard therapy > 1m(Dig, ACE, Diuretic, BB)
Exclusion Criteria
Critical aortic stenosis
Severe coarctation
Coronary artery anomalies
Cardiogenic shock
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of safety and tolerability. Timepoint: 3 months. Method of measurement: Physical examination and clinical symptom.
- Secondary Outcome Measures
Name Time Method ProBNP measurement. Timepoint: 0, 2 weeks, 1, 2, 4 and 6 months. Method of measurement: Lab test.